Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORIC |
---|---|---|
09:32 ET | 3960 | 10 |
09:36 ET | 1400 | 9.86 |
09:38 ET | 100 | 9.86 |
09:45 ET | 300 | 9.73 |
09:50 ET | 196 | 9.695 |
09:52 ET | 100 | 9.715 |
09:54 ET | 500 | 9.78 |
09:56 ET | 1400 | 9.67 |
09:57 ET | 373 | 9.66 |
09:59 ET | 100 | 9.62 |
10:01 ET | 427 | 9.61 |
10:03 ET | 1287 | 9.69 |
10:06 ET | 1117 | 9.64 |
10:08 ET | 1326 | 9.58 |
10:10 ET | 1073 | 9.61 |
10:12 ET | 821 | 9.66 |
10:14 ET | 1200 | 9.65 |
10:15 ET | 500 | 9.61 |
10:17 ET | 1021 | 9.6 |
10:19 ET | 627 | 9.63 |
10:21 ET | 425 | 9.66 |
10:24 ET | 2489 | 9.58 |
10:26 ET | 600 | 9.64 |
10:28 ET | 557 | 9.62 |
10:30 ET | 3753 | 9.61 |
10:32 ET | 656 | 9.655 |
10:33 ET | 400 | 9.695 |
10:35 ET | 1344 | 9.74 |
10:39 ET | 200 | 9.7947 |
10:42 ET | 172 | 9.81 |
10:44 ET | 100 | 9.85 |
10:46 ET | 100 | 9.84 |
10:50 ET | 300 | 9.86 |
10:51 ET | 1970 | 9.85 |
10:53 ET | 100 | 9.83 |
10:55 ET | 100 | 9.8 |
11:02 ET | 200 | 9.83 |
11:06 ET | 3147 | 9.87 |
11:08 ET | 100 | 9.87 |
11:09 ET | 1113 | 9.82 |
11:13 ET | 500 | 9.8 |
11:15 ET | 750 | 9.748 |
11:18 ET | 100 | 9.75 |
11:20 ET | 236 | 9.78 |
11:22 ET | 200 | 9.78 |
11:24 ET | 300 | 9.76 |
11:26 ET | 600 | 9.71 |
11:27 ET | 100 | 9.715 |
11:31 ET | 500 | 9.69 |
11:36 ET | 572 | 9.71 |
11:38 ET | 100 | 9.71 |
11:40 ET | 100 | 9.67 |
11:42 ET | 431 | 9.72 |
11:44 ET | 600 | 9.76 |
11:47 ET | 100 | 9.78 |
11:49 ET | 1200 | 9.8 |
11:51 ET | 1355 | 9.78 |
11:54 ET | 300 | 9.76 |
11:56 ET | 200 | 9.775 |
11:58 ET | 134 | 9.79 |
12:00 ET | 100 | 9.81 |
12:02 ET | 100 | 9.81 |
12:03 ET | 100 | 9.79 |
12:05 ET | 1200 | 9.79 |
12:09 ET | 100 | 9.755 |
12:12 ET | 237 | 9.7565 |
12:14 ET | 155 | 9.7565 |
12:16 ET | 1148 | 9.74 |
12:21 ET | 115 | 9.685 |
12:23 ET | 132 | 9.685 |
12:25 ET | 400 | 9.715 |
12:32 ET | 300 | 9.72 |
12:45 ET | 300 | 9.69 |
12:52 ET | 746 | 9.66 |
12:56 ET | 100 | 9.675 |
12:57 ET | 1637 | 9.65 |
12:59 ET | 300 | 9.65 |
01:10 ET | 211 | 9.635 |
01:14 ET | 2967 | 9.65 |
01:17 ET | 100 | 9.655 |
01:26 ET | 545 | 9.64 |
01:28 ET | 100 | 9.655 |
01:30 ET | 100 | 9.67 |
01:32 ET | 1220 | 9.66 |
01:37 ET | 539 | 9.685 |
01:39 ET | 100 | 9.705 |
01:44 ET | 700 | 9.72 |
01:46 ET | 275 | 9.71 |
01:50 ET | 516 | 9.75 |
01:51 ET | 100 | 9.76 |
01:57 ET | 607 | 9.77 |
02:00 ET | 600 | 9.775 |
02:02 ET | 100 | 9.79 |
02:06 ET | 200 | 9.79 |
02:08 ET | 363 | 9.81 |
02:11 ET | 200 | 9.8 |
02:13 ET | 100 | 9.81 |
02:15 ET | 100 | 9.8 |
02:18 ET | 300 | 9.795 |
02:22 ET | 1200 | 9.86 |
02:24 ET | 1084 | 9.84 |
02:27 ET | 600 | 9.85 |
02:29 ET | 100 | 9.82 |
02:31 ET | 100 | 9.83 |
02:40 ET | 200 | 9.85 |
02:44 ET | 100 | 9.84 |
02:47 ET | 200 | 9.86 |
02:51 ET | 230 | 9.867 |
02:54 ET | 1030 | 9.84 |
02:56 ET | 1273 | 9.86 |
03:02 ET | 100 | 9.86 |
03:03 ET | 100 | 9.86 |
03:05 ET | 422 | 9.86 |
03:07 ET | 907 | 9.84 |
03:09 ET | 100 | 9.83 |
03:12 ET | 100 | 9.865 |
03:14 ET | 774 | 9.85 |
03:16 ET | 141 | 9.85 |
03:18 ET | 100 | 9.85 |
03:21 ET | 100 | 9.85 |
03:23 ET | 100 | 9.85 |
03:25 ET | 3423 | 9.83 |
03:27 ET | 500 | 9.83 |
03:30 ET | 400 | 9.855 |
03:32 ET | 1709 | 9.87 |
03:34 ET | 200 | 9.865 |
03:36 ET | 400 | 9.87 |
03:38 ET | 200 | 9.87 |
03:39 ET | 1356 | 9.85 |
03:41 ET | 443 | 9.85 |
03:43 ET | 2165 | 9.85 |
03:45 ET | 1371 | 9.84 |
03:48 ET | 5595 | 9.75 |
03:50 ET | 2687 | 9.8 |
03:52 ET | 3684 | 9.8 |
03:54 ET | 2832 | 9.78 |
03:56 ET | 1150 | 9.79 |
03:57 ET | 5783 | 9.77 |
03:59 ET | 65728 | 9.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oric Pharmaceuticals Inc | 708.2M | -5.6x | --- |
Opthea Ltd | 706.4M | -1.6x | --- |
Olema Pharmaceuticals Inc | 704.4M | -5.8x | --- |
Erasca Inc | 731.7M | -2.7x | --- |
Terns Pharmaceuticals Inc | 683.6M | -6.2x | --- |
Rapport Therapeutics Inc | 742.9M | -10.6x | --- |
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $708.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.11 |
EPS | $-1.76 |
Book Value | $4.08 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.